Level of topoisomerase IIα expression as a prognostic indicator in patients with breast cancer (literature review)


  • A.A. Samusieva Bogomolets National Medical University, Kyiv, Ukraine,




breast cancer, topoisomerase IIα, topoisomerase inhibitors, anthracycline antibiotics


Topoisomerases are important enzymes that ensure the genomic integrity. It is a target for anthracycline antibiotics which are used in the breast cancer chemotherapy. A series of studies that researched connection between topoisomerase IIα and the sensitivity to chemotherapy with anthracycline antibiotics in patients with breast cancer are considered in the article, however, the predictive value of this marker is still controversial.


Федоренко З.П., Гулак Л.О., Михайлович Ю.Й. та ін. Рак в Україні 2016–2017 // Бюлетень Національного канцер-­реєстру України. — 2018. — № 19. — С. 7.

Ferlay J., Soerjomataram I., Dikshit R. еt al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 // IJC. — 2015. — Vol. 136(5). — Р. 359-386.

Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation // Cell. — 2011. — Vol. 144. — Р. 646-674.

Wang J.C. Interaction between DNA and an Escherichia coli protein ω // J. Mol. Biol. — 1971. — Vol. 55(3). — Р. 523-533.

Gellert M., Mizuuchi K., O’Dea M.H., Nash H.A. DNA gyrase: an enzyme that introduces superhelical turns into DNA // Proc. Natl. Acad. Sci. USA. — 1976. — Vol. 73(11). — Р. 3872-3876.

Woessner R.D., Mattern M.R., Mirabelli C.K. et al. Proli­feration- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells // Cell Growth Differ. — 1991. — Vol. 2. — Р. 209-214.

Fry A.M., Chresta C.M., Davies S.M., Walker M.C., Harris A.L., Hartley J.A., Masters J.R., Hickson I.D. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines // Cancer Res. — 1991. — Vol. 51(24). — Р. 6592-6595.

Деженкова Л.Г., Цветков В.Б., Штиль А.А. Ингибиторы топоизомераз I и II: химическая структура, механизмы действия и роль в химиотерапии опухолей // Успехи химии. — 2014. — T. 83, № 1. — С. 82-94.

Almeids D., Gerhard R., Leitao D. et al. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer // Pathol. Res Pract. — 2014. — Vol. 210(10). — Р. 675-679.

Nikolenyi A., Uhercsak G., Csenki M. et al. Tumour Topo­isomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-Dense Anthracycline-Based Chemotherapy // Pathol. Oncol. Res. — 2012. — Vol. 18. — Р. 61-68.

An X., Xu F., Luo R. et al. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer // BMC Cancer. — 2018. — Vol. 18. — Р. 331.

Norimura S., Kontani K., Kubo T. et al. Candidate biomar­kers predictive of anthracycline and taxane efficacy against breast cancer // J. Cancer Res Ther. — 2018. — Vol. 14(2). — Р. 409-415.

Järvinen T.A., Holli K., Kuukasjärvi Т. et al. Predictive va­lue of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer // Br. J. Cancer. — 1998. — Vol. 77(12). — Р. 2267-73.

Petit T., Wilt M., Velten M. et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy // Eur. J. Cancer. — 2004. — Vol. 40(2). — Р. 205-11.